# 乳腺癌临床试验报告

**生成日期**: 2025-06-07
**查询条件**: 乳腺癌相关的活跃临床试验
**查询范围**: 最近30天内新增或更新的试验
**试验总数**: 10
**智能翻译**: ✅ 已启用

> 📝 **说明**: 本报告提供中英文对照信息，关键医学术语保持原文以确保准确性。

## 试验列表

### 正在招募的试验

## 一项研究Sacituzumab Tirumotecan（Sac-TMT，MK-2870）单药治疗及与Pembrolizumab（MK-3475）联合治疗三阴性乳腺癌患者的研究（MK-2870-011/TroFuse-011）。

<details>
<summary>🔍 查看英文原文</summary>

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

</details>

**试验编号**: NCT06841354  
**正式标题**: 一项第3期、随机、开放标签研究，比较Sacituzumab Tirumotecan（Sac-TMT，MK-2870）单药治疗与联合Pembrolizumab（MK-3475）治疗，与医生选择的治疗方案，在未曾治疗的局部复发不可切除或转移性三阴性乳腺癌患者中的疗效与安全性，这些患者的PD-L1表达CPS小于10（TroFuse-011）。

<details>
<summary>🔍 查看英文原文</summary>

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

</details>  
**疾病条件**: 三阴性乳腺癌病变 (Triple Negative Breast Neoplasms)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 塞替珠单抗 tirumotecan，帕博利珠单抗，抢救用药，紫杉醇，白蛋白结合型紫杉醇，吉西他滨，卡铂。 (Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin)  
**干预类型**: 生物制品，生物制品，药物，药物，药物，药物，药物。 (BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG)  

### 试验信息
**主要发起方**: Merck Sharp & Dohme LLC  
**试验地点**: Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, United States; Renown Regional Medical Center ( Site 0005), Reno, United States; New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque, United States  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 1000  

### 重要日期
**首次提交**: 2025-02-18  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)

---

## 一项研究BL-M07D1与研究者选择的化疗方案在HER2低表达型复发/转移性乳腺癌患者中的比较。 (A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer)

**试验编号**: NCT06957886  
**正式标题**: 一项随机、对照的III期研究，比较BL-M07D1与研究者选择的化疗方案在HER2低表达型复发/转移性乳腺癌患者中的应用。 (A Randomized, Controlled Phase III Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer)  
**疾病条件**: HER2低表达乳腺癌 (HER2-low Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: BL-M07D1、卡培他滨、艾瑞布林、吉西他滨、紫杉醇或白蛋白紫杉醇 (BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel)  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: Sichuan Baili Pharmaceutical Co., Ltd.  
**试验地点**: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Hunan Cancer Hospital, Changsha, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 564  

### 重要日期
**首次提交**: 2025-04-27  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06957886)

---

## 新辅助化疗联合Toripalimab治疗HR+/HER2-乳腺癌：一项随机、开放标签、平行对照的多中心III期研究（NEOTORCH-BREAST04） (Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04))

**试验编号**: NCT06977893  
**正式标题**: 新辅助化疗联合Toripalimab治疗HR+/HER2-乳腺癌：一项随机、开放标签、平行对照的多中心III期研究（NEOTORCH-BREAST04） (Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04))  
**疾病条件**: 英文内容：

HR+/HER2- Breast Cancer

中文翻译：

激素受体阳性/HER2阴性乳腺癌 (HR+/HER2- Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 新辅助化疗联合特瑞普利单抗，新辅助化疗 (Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy)  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: First Affiliated Hospital of Zhejiang University  
**试验地点**: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; The First Affiliated Hospital of Zhejiang University, Hangzhou, China; Zhejiang Cancer Hospital, Hangzhou, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 194  

### 重要日期
**首次提交**: 2025-05-12  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977893)

---

## 一项IIIB期研究，评估卡皮瓦塞特ib与氟维司群联合使用在曾接受内分泌治疗（ET）及CDK4/6抑制剂后复发/进展的晚期乳腺癌患者中的效果，该研究反映了西班牙实际临床实践情况。 (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain)

**试验编号**: NCT06764186  
**正式标题**: 一项IIIB期研究，评估卡皮瓦斯替布与氟维司群联合使用在西班牙临床实践中，针对那些对内分泌治疗（ET）和CDK4/6抑制剂治疗复发/进展的HR+ / HER2-晚期乳腺癌患者中的应用情况。 (A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain)  
**疾病条件**: 局部晚期或转移性乳腺癌 (Locally Advanced or Metastatic Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 氟维司群，卡皮瓦塞替布 (Fulvestrant, Capivasertib)  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: AstraZeneca  
**试验地点**: Research Site, Alicante, Spain; Research Site, Barcelona, Spain; Research Site, Barcelona, Spain  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 100  

### 重要日期
**首次提交**: 2024-11-28  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764186)

---

## 局部使用倍他米松与润肤剂在俯卧位治疗的大胸患者中预防放射性皮炎的比较研究。 (Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position)

**试验编号**: NCT06915857  
**正式标题**: 大型乳房患者在俯卧位治疗中，比较局部使用倍他米松与润肤剂预防放射性皮炎：一项随机第三期临床试验。 (A Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position: A Randomized Phase III Trial)  
**疾病条件**: 乳腺癌，放射性皮炎 (Breast Cancer, Radiation Dermatitis)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 局部使用倍他米松 (Topical Betamethasone)  
**干预类型**: DEVICE  

### 试验信息
**主要发起方**: Sunnybrook Health Sciences Centre  
**试验地点**: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 276  

### 重要日期
**首次提交**: 2025-03-17  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06915857)

---

## 新辅助SNF精准治疗三期临床试验 (Neoadjuvant SNF Precision Therapy Phase III)

**试验编号**: NCT06913777  
**正式标题**: 一项开放标签、多中心、随机对照的III期临床试验，研究基于SNF分类的早期或局部晚期HR+/HER2-乳腺癌新辅助化疗，是否联合精准医疗药物。 (An Open-Label, Multicenter, Randomized Controlled Phase III Clinical Study of Neoadjuvant Chemotherapy Based on SNF Classification With or Without Precision Medicine Agents for Early-Stage or Locally Advanced HR+/HER2- Breast Cancer)  
**疾病条件**: 新辅助治疗疗法 (Neoadjuvant Therapy)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 针对性治疗药物：SNF2 -阿德雷利单抗+法米替尼；SNF3 -氟唑帕利；SNF4 -阿帕替尼，化疗（wP-EC） (Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC))  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: Fudan University  
**试验地点**: Fudan University Shanghai Cancer Center, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 404  

### 重要日期
**首次提交**: 2025-03-30  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06913777)

---

## 一项评估Inavolisib联合CDK4/6抑制剂及来曲唑对比安慰剂+CDK4/6抑制剂和来曲唑治疗内分泌敏感型PIK3CA突变、激素受体阳性、HER2阴性晚期乳腺癌患者的疗效和安全性的研究。 (A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer)

**试验编号**: NCT06790693  
**正式标题**: 一项三期、多中心、随机、双盲、安慰剂对照研究，评估Inavolisib联合CDK4/6抑制剂和来曲唑对比安慰剂联合CDK4/6抑制剂和来曲唑，在激素受体阳性、HER2阴性、内分泌敏感型PIK3CA突变晚期乳腺癌患者中的疗效和安全性。

<details>
<summary>🔍 查看英文原文</summary>

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

</details>  
**疾病条件**: 乳腺癌 (Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 伊纳olisib，安慰剂，CDK4/6抑制剂，来曲唑 (Inavolisib, Placebo, CDK4/6i, Letrozole)  
**干预类型**: 药物，药物，药物，药物。 

（由于提供的英文内容仅为重复的单词"DRUG"，翻译结果亦重复以保持原文形式。） (DRUG, DRUG, DRUG, DRUG)  

### 试验信息
**主要发起方**: Hoffmann-La Roche  
**试验地点**: Northwest Georgia Oncology Centers PC - Marietta, Marietta, United States; Springfield Clinic, Springfield, United States; Nebraska Cancer Specialists, Grand Island, United States  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 450  

### 重要日期
**首次提交**: 2025-01-14  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790693)

---

## 研究PF-07220060与来曲唑联合治疗未接受过晚期/转移性疾病抗癌治疗的人HR阳性HER2阴性乳腺癌成人患者的研究。 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease)

**试验编号**: NCT06760637  
**正式标题**: 一项干预性、开放标签、随机、多中心的第3期研究，比较PF-07220060联合来曲唑与CDK4/6抑制剂联合来曲唑治疗18岁以上、激素受体（HR）阳性、HER2阴性晚期/转移性乳腺癌患者，且此前未接受过针对晚期/转移性疾病的系统性抗癌治疗（FOURLIGHT-3研究）。

<details>
<summary>🔍 查看英文原文</summary>

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

</details>  
**疾病条件**: 乳腺癌 (Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: PF-07220060，来曲唑，阿贝西利，帕博西尼，瑞博西尼。 (PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib)  
**干预类型**: 药物，药物，药物，药物，药物。 (DRUG, DRUG, DRUG, DRUG, DRUG)  

### 试验信息
**主要发起方**: Pfizer  
**试验地点**: Ironwood Cancer & Research Centers, Chandler, United States; Ironwood Cancer & Research Centers, Gilbert, United States; Ironwood Cancer & Research Centers, Glendale, United States  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 1020  

### 重要日期
**首次提交**: 2024-12-11  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760637)

---

## JSKN003 与曲妥珠单抗埃坦塞 (T-DM1) 用于HER2阳性晚期乳腺癌的比较研究。 (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer)

**试验编号**: NCT06846437  
**正式标题**: 一项随机、对照、开放标签、多中心、Ⅲ期临床试验，比较JSKN003与恩坦辛曲妥珠单抗（T-DM1）在HER2阳性晚期乳腺癌患者中的疗效与安全性。 (A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects)  
**疾病条件**: 不可手术的局部晚期或HER2阳性乳腺癌转移患者参与者 (Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: JSKN003，曲妥珠单抗-emtansine（T-DM1） (JSKN003, Trastuzumab emtansine (T-DM1))  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: Shanghai JMT-Bio Inc.  
**试验地点**: Fudan University Shanghai Cancer Center, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 228  

### 重要日期
**首次提交**: 2025-01-06  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846437)

---

## 比较竖脊肌平面阻滞与肋间前肌平面阻滞在改良根治性乳房切除术后镇痛效果方面的差异。 (Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy)

**试验编号**: NCT06947330  
**正式标题**: 比较超声引导下竖脊肌平面阻滞与超声引导下前锯肌平面阻滞在改良根治性乳腺切除术后镇痛效果方面的差异。 (Comparison Between Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy)  
**疾病条件**: 改良根治性乳腺切除术，乳腺癌 (Modified Radical Mastectomy, Breast Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE3  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 单侧竖脊肌群，单侧前锯肌群 (Unilateral Erector Spinae group, Unilateral Serratus Anterior group)  
**干预类型**: 程序，程序

（由于您未提供具体的英文内容，我无法进行具体翻译。如果提供具体文本，我将能够准确翻译。） (PROCEDURE, PROCEDURE)  

### 试验信息
**主要发起方**: Kholoud Usama  
**试验地点**: Faculty of Medicine, Ain-Shams University, Cairo, Egypt  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 100  

### 重要日期
**首次提交**: 2025-04-13  
**最后更新**: N/A  

### 联系信息
**联系人**: N/A  
**电话**: N/A  
**邮箱**: N/A  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947330)

---

